Authors
Molchanov I.P.1, Dimertsev A.V.2, Zuev A.A.2
1 Kursk State Medical University, Kursk
2 Pirogov National Medical and Surgical Center, Moscow
Abstract
One of the rare neoplasms of the pyramid of the temporal bone is an endolymphatic sac tumor (ELST). The progression of the disease is characterized by an increase in neurological symptoms, including sensorineural hearing loss, facial nerve paresis, and headache. Neurosurgical tactics differ from standard methods of treating tumors because of the histoanatomical characteristics of ELST. This article describes a case of successful treatment of an endolymphatic sac tumor. Microsurgical removal of ELST is a best treatment, whereas radiosurgery has limited possibilities. This method used in the postoperative period with residual volumes of pathological tissue or tumor recurrence. We use retrolabyrinthine access with subtotal petrosectomy with neuronavigation and neurophysiological monitoring. Embolization of the vessels feeding the tumor was not performed before operation. Autohemotransfusion system, named Cell-Saver, and hemostatic materials were used intraoperatively. This method is safety and effectiveness, providing a relatively small amount of blood loss, complete decompression of intracranial structures, including the bulbar group of cranial nerves, partial - the VII and VIII pairs, which, however, was accompanied by regression of neurological symptoms and a satisfactory degree of resection of the tumor. This tactic can be recommended for the treatment of endolymphatic sac tumor, since there are lower risks of relapses and surgical complications for the patient.
Keywords: endolymphatic sac tumor, neurophysiological monitoring, microsurgical treatment, petrosectomy, hemostatic materials.
References
1. Woods RSR, Naude A, O’Sullivan JB, et al. Management of Temporal Bone Malignancy in Ireland. J Neurol Surg B Skull Base. 2020; 81(6): 680-685. doi: 10.1055/s-0039-1696723.
2. Han JJ, Lee DY, Kong SK, et al. Clinicoradiologic Characteristics of Temporal Bone Meningioma: Multicenter Retrospective Analysis. Laryngoscope. 2021; 131(1): 173-178. doi: 10.1002/lary.28534.
3. Tang JD, Grady AJ, Nickel CJ, et al. Systematic Review of Endolymphatic Sac Tumor Treatment and Outcomes. Otolaryngol Head Neck Surg. 2023; 168(3): 282-290. doi: 10.1177/ 01945998221108313.
4. Diab KhMA, Daykhes NA, Saydulaev VA, et al. Endolymphatic sac tumor: rewiev of literature. Meditsinskiy Sovet. 2022; 16(8): 150-159. (In Russ.)
5. Torres JAGB, Ferreira-Pinto PHC, Ferreira DBCO, et al. Endolymphatic sac tumor: An urgent case presenting acute intracranial hypertension successfully treated with suboccipital decompressive craniectomy – 8 years of follow-up. Surg Neurol Int. 2024; 15: 166. doi: 10.25259/SNI_34_2024.
6. Bausch B, Wellner U, Peyre M, et al. Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry. Head Neck. 2016; 38: E673-E679. doi: 10.1002/hed.24067.
7. Gioacchini FM, Kaleci S, Chiarella G, et al. Symptoms and clinical features in patients affected by endolymphatic sac tumor: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2022; 279(11): 5081-5088. doi: 10.1007/s00405-022-07469-6.
8. Lyons TP, Barry L, Sataloff RT. Endolymphatic Sac Tumor. Ear Nose Throat J. 2022. doi: 10.1177/01455613221139408.
9. Olcott C, Strasnick B. A blue middle ear mass: Cholesterol granuloma mimicking a glomus tumor and endolymphatic sac tumor. Am J Otolaryngol. 2017; 38(1): 100-102. doi:10.1016/j.amjoto.2016.09.013
10. Wick CC, Eivaz NA, Yeager LH, et al. Case Series and Systematic Review of Radiation Outcomes for Endolymphatic Sac Tumors. Otol Neurotol. 2018; 39(5): 550-557. doi: 10.1097/MAO.0000000000001804.
11. Balasubramaniam S, Deshpande RB, Misra BK. Gamma knife radiosurgery in jugular foramen endolymphatic sac adenocarcinoma. J Clin Neurosci. 2009; 16(5): 710-711. doi: 10.1016/j.jocn.2008.07.086.
12. Schipper J, Maier W, Rosahl SK, et al. Endolymphatic sac tumours: surgical management. J Otolaryngol. 2006; 35(6): 387-394. doi: 10.2310/7070.2006.0082.
13. Bambakidis NC, Megerian CA, Ratcheson RA. Differential grading of endolymphatic sac tumor extension by virtue of von Hippel-Lindau disease status. Otol Neurotol. 2004; 25(5): 773-781. doi: 10.1097/00129492-200409000-00021.
14. Poletti AM, Dubey SP, Barbò R, et al. Sporadic endolymphatic sac tumor: its clinical, radiological, and histological features, management, and follow-up. Head Neck. 2013; 35(7): 1043-1047. doi: 10.1002/hed.22962.
15. Guo F, Zhang L, Mo L. Long experience for the diagnosis and treatment of sporadic endolymphatic sac tumor in a single center. Clin Neurol Neurosurg. 2020; 197: 106078. doi: 10.1016/j.clineuro.2020.106078.
16. Melone AG, D’Elia A, Santoro F, et al. Intracranial hemangiopericytoma – our experience in 30 years: a series of 43 cases and review of the literature. World Neurosurg. 2014; 81(3-4): 556-562. doi: 10.1016/j.wneu.2013.11.009.
17. Sykopetrites V, Piras G, Giannuzzi A, et al. The endolymphatic sac tumor: challenges in the eradication of a localized disease. Eur Arch Otorhinolaryngol. 2021; 278(7): 2297-2304. doi: 10.1007/s00405-020-06323-x.
18. Künzel J, Agaimy A, Hornung J, et al. Sporadic endolymphatic sac tumor – a diagnostic and therapeutic challenge. Int J Clin Exp Pathol. 2014; 7(5): 2641-2646.
